Rockefeller Capital Management L.P. Sells 871 Shares of Genmab A/S (NASDAQ:GMAB)

Rockefeller Capital Management L.P. decreased its position in Genmab A/S (NASDAQ:GMAB) by 5.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,174 shares of the company’s stock after selling 871 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Genmab A/S were worth $397,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Oppenheimer Asset Management Inc. raised its stake in shares of Genmab A/S by 26.3% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock worth $5,480,000 after purchasing an additional 45,376 shares in the last quarter. Choreo LLC purchased a new position in shares of Genmab A/S in the 2nd quarter worth approximately $776,000. Renaissance Technologies LLC raised its stake in shares of Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after purchasing an additional 103,859 shares during the period. US Bancorp DE increased its stake in shares of Genmab A/S by 16.0% during the 3rd quarter. US Bancorp DE now owns 171,669 shares of the company’s stock worth $4,185,000 after purchasing an additional 23,723 shares during the last quarter. Finally, Natixis Advisors LLC lifted its position in shares of Genmab A/S by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock valued at $5,036,000 after buying an additional 47,437 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $21.83 on Wednesday. The firm has a market capitalization of $14.45 billion, a price-to-earnings ratio of 21.33, a PEG ratio of 0.68 and a beta of 0.96. The stock’s 50-day simple moving average is $22.36 and its 200-day simple moving average is $25.24. Genmab A/S has a fifty-two week low of $20.34 and a fifty-two week high of $32.88.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). The business had revenue of $816.10 million during the quarter, compared to analysts’ expectations of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same quarter in the prior year, the firm earned $0.47 EPS. As a group, equities analysts forecast that Genmab A/S will post 1.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on GMAB shares. JPMorgan Chase & Co. restated a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Redburn Atlantic initiated coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating for the company. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Wednesday, October 16th. BMO Capital Markets restated an “outperform” rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $31.00 price objective on shares of Genmab A/S in a research note on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.